Susanne Schaffert, Ph.D., Sidonie Golombowski-Daffner was appointed Chairperson and President of Advanced Accelerator Applications (AAA), a Novartis company in October 2019. Prior to this, Sidonie was General Manager, Novartis Pharma GmbH Nürnberg and Country President Germany since 2017. In this capacity, she was also a member of the Supervisory Boards of Novartis Deutschland GmbH and Novartis Pharma GmbH, Country Executive Committee, Innovative Medicines Committee and Pharma Leadership Team Region Europe. As Country President Germany, Sidonie oversaw 7,500 associates across 12 sites, generating $3.9 billion in sales. During her tenure as General Manager of Novartis Pharma Germany, she led the marketing of products in Rare Diseases, Immunology & Dermatology, Neuroscience, Cardiology, Respiratory and Ophthamology. Under her leadership, the team launched the first Cell and Gene therapy in the Pharma Division, Luxturna, for Ophthamology. From 2014 to 2017, Sidonie served as Novartis Worldwide Franchise Head, Respiratory in Basel. She first joined Novartis in 2011, as Head of Primary Care for Germany. Prior to this, Sidonie spent 10 years at Sanofi and its predecessor companies, Sanofi-Aventis and Sanofi-Synthelabo in a variety of leadership positions with increasing responsibility across the pharmaceutical and generic sectors in Germany, at the corporate headquarters in France, and in the Asia-Pacific region. Sidonie first started her career as a management consultant at Roland Berger, where she spent five years advising pharmaceutical clients in the US, Europe, Russia and Japan. Sidonie holds a Ph.D. in Neuroscience from Ludwig Maximilian University of Munich (Germany) and has additional qualifications in Business Administration.

Jessica Toepfer was appointed to the board of Advanced Accelerator Applications (AAA) in January 2018, following the completion of a tender offer for the company by Novartis. She is a board member of Novartis Group France, as well as the Country CFO and Pharma CFO for Novartis France, since May 2016. With 20 years of finance and business performance experience in the pharmaceutical industry, Jessica has worked across a range of geographies and therapeutic areas with increasing responsibility. She joined Novartis in 1998, as part of Group BPA’s Finance Development Program and after a rotation in Basel, had assigntments over the next four years in Consumer Health Switzerland & Belgium and Pharma Morocco, before becoming Country CFO Norway, from 2003 to 2006. Jessica then returned to Basel as Finance Head Business Franchise CVM and in 2008 was named Head of Business Planning & Analysis Latin America based in Miami. In 2011, she returned to Europe as Country CFO in Portugal and in December 2013, was named CFO Middle East & North Africa (MENA) Cluster in Dubai managing a portfolio of 18 countries. Jessica holds a Bachelor of Science degree in Foreign Service from Georgetown University in Washington D.C., and a Master’s of Business Administration from HEC School of Management in Paris.

Katherine Betz-Doherty is Head of People & Organization for Advanced Accelerator Applications (AAA), a Novartis company. Prior to joining AAA in 2018, Katherine served as Head of Human Resources for three Novartis Group global functions (Human Resources, Communications & Advocacy and Global Health and Corporate Responsibility). In this position she partnered with leadership teams across the organizational matrix to embed talent, capabilities and a culture agenda. Since joining Novartis in 1999, Katherine has worked on multiple transformational efforts in the areas of acquisitions, innovative business models, and capability development while building people and patient centric cultures. From 2013 to 2016, she was Head of Human Resources for Genoptix, a molecular diagnostics lab and a start-up business acquired by Novartis. Before this she spent several years at Novartis Pharmaceuticals in compensation, talent management, organization development and lastly leading HR Business Partner teams in the Specialty Medicine and Business functions groups for the US General Medicine unit. Katherine started her career in Human Resources working with several well-known global leaders in high tech and consulting, including Dell Computers, Cap Gemini and Anderson Consulting. Katherine holds a Bachelor degree in Labor and Industrial Relations from Pennsylvania State University and a Master degree in Management and Organization Development from College of St. Elizabeth in New Jersey.

Leo Bronfman is Head of Legal and Compliance for Advanced Accelerator Applications (AAA), a Novartis company. Prior to joining AAA in September 2018, Leo spent three years at Novartis Oncology, where he was Director, Pharmaceutical Counsel and then Executive Director, Senior Pharmaceutical Counsel where he supported business development and licensing, alliance management and compliance functions. Before Novartis Oncology, Leo held the position of Senior Corporate Counsel for Sandoz U.S., where his responsibilities included legal support for business development and licensing transactions, product-related mergers and acquisitions and technical operations. After graduating from law school and prior to joining Sandoz U.S., Leo practiced law as a mergers and acquisitions corporate associate at various top law firms in New York, where he advised public and private companies on mergers and acquisitions, complex licensing and collaboration transactions, as well as general commercial and finance transactions Leo holds a Juris Doctor degree magna cum laude from Fordham University School of Law, and holds a Bachelor of Science degree magna cum laude from Hunter College, City University of New York.

Rachel Levine is Head of Communications and Patient Advocacy for Advanced Accelerator Applications (AAA), a Novartis company. Prior to joining AAA in 2016, Rachel spent eight years at Cleveland BioLabs, Inc., a publicly traded biotechnology company, as Director of Corporate Development and Communications and then as Vice President of Investor Relations. During her tenure, she led financing activities, investor and media relations, and internal communications, and supported business development and government relations activities. Rachel has specialized in the healthcare sector (including biotechnology, specialty pharmaceuticals, managed care, healthcare services, and medical device and delivery) since 2000. From 2005 to 2007, Rachel served as Managing Director for Grayling, a global integrated communications firm and division of Huntsworth PLC. Before this, she was Managing Director at The Anne McBride Company, a global investor and public relations advisory. Rachel holds a Bachelor’s of Business Administration, with honors from the University of Massachusetts (Amherst, MA).

Jordi Vall-llossera is Head of Quality Assurance for Advanced Accelerator Applications (AAA), a Novartis company. Prior to joining AAA in 2018, Jordi served as Global Head of Supply Chain Quality Assurance for Novartis. Before this he was Head of Pharma Supply Chain Quality Assurance and Responsible Person for the Distribution licenses for Novartis Pharma AG and Novartis Pharma Services AG. From 2014 to 2015, Jordi held the position of Global Quality Process Lead for within the Novartis Pharma Quality organization and from 2010 to 2014, he was Global Quality Operations Manager for Products. Jordi first started his tenure at Novartis in 2005, as a Quality IT Manager at a manufacturing site in Spain and moved to Basel in 2009, to oversee the implementation of a Laboratory Information Management System at all Novartis Pharma manufacturing sites. He spent the first five years of his professional career as a Quality Management and Business Consultant specialized in operations and information technology at Accenture (Anderson Consulting) and in private practice. Jordi holds a degree in Technical Agricultural Engineering from the Polytechnic University of Catalonia and a degree in Agronomical Engineering from the University of Lleida, both in Spain. He has also completed a special Quality Management Program at the Escuela Organizacion Industrial in Barcelona, Spain.

Andrew Cavey, M.D., was appointed Global Program Head, Prostate Cancer for Advanced Accelerator Applications (AAA), a Novartis company, in September 2020. He is also a member of the Oncology Development Leadership Team at Novartis. Prior to joining AAA, Andrew served as Global Program Head, Benign Hematology, in the Hematology Development Unit of Novartis from 2017 to 2020, where he led the portfolio’s development and life cycle management activities. From 2015 to 2017, Andrew was the Cardio-Metabolic Business Unit Head in China for Novartis Pharmaceuticals and from 2012-2015, Strategic Assistant to the CEO. Prior to joining Novartis in 2012, Andrew was a consultant at McKinsey & Company from 2008 to 2012, and previously a diplomat in the British Foreign and Commonwealth Office from 2006 to 2007. From 2002 to 2006, Andrew worked as a physician in the United Kingdom’s National Health Service. He is a Member of the United Kingdom’s Royal College of Physicians and a Board member of the charity, Parkinson’s UK. Andrew holds his Medical and Masters in Physiological Sciences degrees from the University of Oxford, and a Master of Public Health from Harvard University.

Stephen Moran, Ph.D., was appointed Global Program Head, Neuroendocrine Tumors & Other Radiosensitive Cancers for Advanced Accelerator Applications (AAA), a Novartis company in October 2020. He is also a member of the Oncology Development Unit Leadership Team at Novartis. Prior to joining AAA, Stephen was Global Head of Novartis Strategy, since 2016. As Strategy Global Head, Stephen played a key role in defining the company’s strategy, prioritizing critical actions needed to deliver on the mission to discover new ways to extend and improve peoples’ lives. He also led numerous strategic initiatives, including gene therapy (AveXis, now Novartis Gene Therapies), RNA (The Medicines Company), precision medicine and digital strategies. Stephen joined Novartis in 2015 as Strategic Assistant to the CEO, a position he held for two years. Prior to this, he was an associate principal at McKinsey & Company serving as a leader in the healthcare practice. At McKinsey, Stephen focused on health system sustainability, research and development strategy, and the economic analysis of clinical interventions across disease pathways. Stephen holds a Bachelor of Arts and a Master of Science in Biochemistry from the University of Cambridge in the United Kingdom, including an undergraduate exchange program at the Massachusetts Institute of Technology. He also received a Doctorate from the University of Oxford in Biophysics where he lectured on thermodynamics, quantum mechanics and electromagnetism as applied to biology. Stephen has also been a guest lecturer in strategy at the University of St. Gallen International Executives MBA, masters and bachelor courses, and received the Young Investigator of the Year award in 2006 from Biochemical Journal.

Scott Cameron, M.D., Ph.D., was appointed Head, Radioligand Therapy (RLT) Early Clinical Development for Advanced Accelerator Applications, a Novartis company, in September 2020. Prior to joining AAA, Scott served as Executive Clinical Program Leader, Oncology, Translational Clinical Oncology (TCO) with the Novartis Institutes for BioMedical Research (NIBR) in Cambridge, since 2017. From 2010 to 2017, Scott served as Director, and later as Senior Director and Clinical Program Leader, TCO, at NIBR where he was responsible for the design, conduct and results reporting of clinical studies investigating new cancer therapies. He directed multiple programs within TCO and led the immune-oncology working group, developing a deep understanding of translational oncology. Prior to joining Novartis, Scott was Director of Research at Children’s Medical Center in Dallas, Texas and also served as Co-Chair, Development and Cancer Scientific Program at the Simmons Cancer Center in Dallas from 2006 to 2010. Earlier in his career, Scott spent 12 years at Harvard/Massachusetts Institute of Technology (MIT), where he trained to become a pediatric hematologist/oncologist. He then joined the faculty at University of Texas Southwestern Medical Center in Dallas, where he led the genetics program and cared for pediatric cancer patients. Other academic appointments included Instructor in Pediatrics at Harvard Medical School, as well as Attending Physician at Children’s Hospital and the Dana-Faber Cancer Institute, both in Boston, Massachusetts. Scott holds a medical doctorate from Harvard Medical School, Harvard-MIT Division of Health Sciences and Technology. He also completed his Ph.D. in Genetics at Cold Spring Harbor Laboratories, State University of New York, Stony Brook, and earned a B.A. in Chemistry at The Johns Hopkins University in Baltimore, Maryland.

Thomas Reiner, Ph.D., was appointed Head, Radioligand Therapy (RLT) Drug Discovery for Advanced Accelerator Applications (AAA), a Novartis Company, in July 2021. He serves as Executive Director, Radioligand Therapy Lead, at the Novartis Institutes for BioMedical Research (NIBR) and is also a member of the Oncology Leadership Team at Novartis. Prior to joining AAA, Thomas served as an Assistant/Associate Member and Laboratory Head at Memorial Sloan Kettering Cancer Center from 2012 to 2021. During this same period, he also held affiliations as an Assistant/Associate Professor at Gerstner Sloan Kettering Graduate School of Biomedical Sciences and as Associate Professor at Weill Cornell Medical College. He was also a Member of the Sloan Kettering Institute Chemical Biology Program from 2018 to 2021. From 2011 to 2012, Thomas served as an Instructor at Harvard Medical School/Massachusetts General Hospital, and previously as a Postdoctoral Fellow at the Center for Systems Biology at Massachusetts General Hospital from 2009 to 2011. During his academic career, Thomas focused his research on small molecule-, peptide- and nanoparticle-based probes for imaging and radiotherapy, and on the design of companion tools for quantifying target engagement and predicting drug susceptibility. Thomas received his Ph.D. from the Technical University of Munich, Germany, where he trained as a synthetic chemist.